Yamami Co. (2820)
Market Closed
7 Aug, 06:00
JPX 
¥
5,080. 00
-40
-0.7812%
¥
- Market Cap
- P/E Ratio
- Div Yield
6,000 Volume
- Eps
¥ 5,120
Previous Close Want to track 2820 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
2820 closed Friday lower at ¥5,080, a decrease of -0.7812% from Thursday's close, completing a monthly increase of 4.4193% or ¥215. Over the past 12 months, 2820 stock gained 2.834%.
2820 pays dividends to its shareholders, with the most recent payment made on Jun 29, 2026. The next estimated payment will be in In 4 months on Dec 29, 2026 for a total of ¥46.
The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
2820 Chart
Yamami Co. (2820) FAQ
What is the stock price today?
The current price is ¥5,080.00.
On which exchange is it traded?
Yamami Co. is listed on JPX.
What is its stock symbol?
The ticker symbol is 2820.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Yamami Co. ever had a stock split?
No, there has never been a stock split.
Yamami Co. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | JPX Exchange | JP3943100002 ISIN |
| Hong Kong Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
The Global X China Biotech ETF is an exchange-traded fund designed to provide exposure to Chinese companies operating within the biotechnology sector. Its primary function is to track the performance of the Solactive China Biotech Index, which includes Chinese businesses involved in the development and commercialization of biotechnological products and services. This ETF allows investors to gain insight into a burgeoning market characterized by significant innovation and growth potential, as China's biotechnology industry benefits from increased government support, growing healthcare demands, and a shift towards advanced medical solutions. The Global X China Biotech ETF impacts sectors such as pharmaceuticals, healthcare, and bioengineering by concentrating on companies specialized in gene editing, cellular therapy, and novel drug development. In the financial market, it plays a crucial role for investors seeking diversified exposure to cutting-edge Chinese biotech firms without the need to pick individual stocks, thereby offering a streamlined approach to participating in a major segment of China's rapidly expanding healthcare landscape.
Contact Information
Address: -
Phone: +82 (0)23 774 2222
